Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
Artikelnummer1415
TidsskriftCancer research
Vol/bind81
Udgave nummerSuppl. 13
ISSN0008-5472
DOI
StatusUdgivet - jul. 2021
BegivenhedAACR Annual Meeting 2021 - Philadelphia, USA
Varighed: 10. apr. 202115. apr. 2021

Konference

KonferenceAACR Annual Meeting 2021
Land/OmrådeUSA
ByPhiladelphia
Periode10/04/202115/04/2021

Citationsformater